BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12684644)

  • 1. Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.
    Shimada S; Yagi Y; Kuramoto M; Aoki N; Ogawa M
    Oncol Rep; 2003; 10(3):687-91. PubMed ID: 12684644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient therapy with irinotecan and low-dose cisplatin for metastatic colorectal cancer resistant to 5-fluorouracil.
    Shimada S; Yagi Y; Shiomori K; Kuramoto M; Aoki N; Ogawa M
    Oncol Rep; 2002; 9(4):783-7. PubMed ID: 12066209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
    Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
    Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
    Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
    Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
    Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
    Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
    Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K
    Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
    Yilmaz U; Oztop I; Alacacioglu A; Yaren A; Tarhan O; Somali I
    Chemotherapy; 2006; 52(5):264-70. PubMed ID: 16873996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
    BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.
    Shimada S; Hayashi N; Marutsuka T; Baba Y; Yokoyama S; Iyama K; Ogawa M
    Surg Today; 2002; 32(12):1075-80. PubMed ID: 12541026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
    Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
    Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
    Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
    Nakayama N; Tanabe S; Koizumi W; Higuchi K; Sasaki T; Nakatani K; Shimoda T; Nishimura K; Kobayashi N; Mitomi H; Saigenji K
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1641-4. PubMed ID: 17108732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
    Shitara K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Ura T; Muro K
    Oncology; 2010; 79(3-4):211-8. PubMed ID: 21358209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer.
    Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW
    Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
    Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
    Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.
    Tsutsumi S; Yamaguchi S; Ide M; Tsuboi K; Fukasawa T; Yamaki S; Asao T; Kuwano H
    Hepatogastroenterology; 2006; 53(68):196-200. PubMed ID: 16608023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
    Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.